Endocrine Abstracts

Introduction: GH therapy (rhGH) improves growth outcome in children born small for gestational age (SGA). Growth velocity is maximum in the first year of therapy. Early diagnosis and treatment optimizes the final height.Objectives: Evaluation of efficacy and safety profile in the first 3 years of rhGH treatment in ten SGA children.Methods: The study enrolled ten SGA children (6 boys, 4 girls). All patients were given a mean dose of...

Introduction: Somatostatin analogs, formerly used as adjuvants in acromegaly treatment, are widely used as primary treatment today.Objective: To investigate the efficacy of octreotide therapy in acromegalic patients as primary or secondary therapy.Materials and methods: Four acromegalic patients diagnosed at the Endocrinological Clinic (males, mean age 35–75 years, age range 26–49 years, all patients with macroadenoma) we...

Introduction: Growth hormone (rhGH) is an effective treatment for short children born small for gestational age (SGA) who fail to demonstrate catch-up growth by 2–4 years of age. This children usually do not have classical GH deficiency, but either low GH secretion or reduced sensitivity to GH. The goals of therapy are to achieve a normal height in early childhood and an adult height within the normal target range.Objectives: Evaluation of efficacit...

Introduction: Osteogenesis Imperfecta (O.I.) is a genetic disorder commonly known as brittle bone disease. The majority of people with O.I. have a mutation in one of two genes, COL 1A1 or COL 1A2, that encode type I collagen. In most families, O.I. is inherited in an autosomal dominant pattern. Dual Energy X-ray Absorptiometry - bone mineral density (DXA-BMD) test provides information about bone quantity, not quality. The bisphosphonates - treatment can minimizing fractures by...

The last decade has provided major progress in the development of highly specific and selective pharmacological agents that have facilitated a more aggressive approach to the treatment of patients with acromegaly. Initial transsphenoidal surgery still appears to be the first line of treatment, but in many cases the biochemical cure targets are not reached and the patient needs adjuvant therapy. Somatostatin analogues have become the mainstay of the medical treatment of acromeg...

Cushing’s disease is relatively rare and affects most commonly adults aged 20 to 40. It is associated with high morbidity and mortality; early detection and diagnosis of Cushing’s disease may lead to decreased this two facts and improved quality of life.We present a 32-year-old man with abdominal purple striae, central obesity with typical ‘moon face’ and oscillatory blood pressure values.Hormonal exams revealed...